Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.
about
Competition between two MHC binding registers in a single peptide processed from myelin basic protein influences tolerance and susceptibility to autoimmunity.Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blockingAntigen-specific tolerance as a therapy for experimental autoimmune encephalomyelitis.EAE: a model for immune intervention with synthetic peptides.Epitopes and idiotypes in experimental autoimmune uveitis: a review.Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptorCyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease.A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses.A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis.Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide.Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha productionPrevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not by tolerated peptides.Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year.Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogsA role for CD4+ T-cell subsets producing a selective pattern of lymphokines in the pathogenesis of human chronic inflammatory and allergic diseases.A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.The presentation of self-peptides: tolerance and competition.Prospects for immunotherapy directed to the T cell receptor in human autoimmune disease.Do Natural T Regulatory Cells become Activated to Antigen Specific T Regulatory Cells in Transplantation and in Autoimmunity?Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides.Inhibition of antigen presentation in vitro and in vivo by MHC antagonist peptides.A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.Inhibition of T cell activation by MHC blockade.CD4⁺ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia.Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis?Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.Immunomodulation of experimental autoimmune uveoretinitis: a model of tolerance induction with retinal antigens.Approaches to the treatment of central nervous system autoimmune disease using specific neuroantigen.Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules.T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis.Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone.Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses.Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.Borrelia burgdorferi activates a T helper type 1-like T cell subset in Lyme arthritis.Therapeutic peptides that block interaction of T cells with MHC in experimental allergic encephalomyelitis.Genetics and autoimmunity.
P2860
Q30442985-0C080105-01E3-4954-A7A0-14133E086C00Q34830749-C8F7F2D7-7CE2-4097-B4D1-9EE34FE60593Q35173096-C9157C7D-09CE-41D1-B906-5840AA068065Q35173105-B4338B18-911A-41F7-82B2-5FC201498F7AQ35482896-B3652721-DD08-415E-BE3C-00301259C70FQ35607371-84E7ABB1-3BF2-43C7-A127-1BF7E99EBC70Q36082074-FC3DFBFD-EC0C-4CF7-9F9A-6E181A8D811EQ36083197-7A91521B-62FC-46A2-98E7-7F6509D2FC06Q36231694-68CE03E3-AEAA-48ED-B947-C690B06FE928Q36327377-1170D916-8C5D-4A3B-B169-A96EC8ECB1AAQ36361727-1FF50513-DB25-400B-B2B9-06835E371E11Q36364188-728A3F6F-A8C2-4C18-977A-A5E92A563876Q36365300-33DADA9A-37BB-463D-ACB2-54B36527E433Q36370956-72B4038F-425E-4AC4-A836-C9D276D7BD3FQ36445171-31C6310A-F765-489E-864A-6C3094993584Q36539219-CB044B4A-E1EA-4121-9AB2-5C1B6DEB3CBEQ36562710-BEE990F7-E87E-4FAB-AE35-CB6022DE7490Q36676941-A449B7AB-25E6-4FD5-80AC-D2BF5934EAACQ36715655-D7983917-17B2-48DF-B132-4749BE666ADAQ37065735-C273646E-E89E-4FD8-8AF0-FE89E1C146D0Q37353611-E0AB52FD-1014-4099-BD1F-FC48CC3AD499Q37513296-861FBAD3-32CC-4C29-A530-479BC8895670Q37575900-5E4C79EF-94AD-46D5-A206-21B42A704195Q37611832-758A9F08-643A-4CB4-961E-DB9643D038A2Q37804401-F28853F5-05AF-4C2C-B936-DD20975711C4Q38910238-41BCFB70-F165-49DB-8579-28BDBF74CE68Q39706642-663C77D3-1C12-4312-8D59-6ED5A391F142Q40437100-3D320731-FFD4-4D58-87AD-601AE1CFFC5DQ40662599-FD8B97FA-F29F-426B-AFC7-3C308B86D5C3Q40862395-3CB1BCA7-C789-4D13-A29C-1E69E9AC08F0Q40945287-3582A08C-26A9-4E44-95DF-DAD8A7E77B2EQ41547123-21334857-4DB6-486B-AB69-E43086A48723Q41605976-5123336E-845C-4A10-B32A-13EEC2A927D6Q41881939-7B0BAEA8-92BB-4C8D-8327-31F41B16BC56Q41940214-D1923C44-ABC4-4C27-9BBE-E9CE38B89728Q42155195-613C9347-8736-4BD3-B943-F5A85696D305Q46583951-8AC535D2-D038-419B-ACAC-6C6BFFCC932DQ53681009-09B42F22-B830-43D8-A59F-0A6F01EBABB8
P2860
Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.
description
1989 nî lūn-bûn
@nan
1989 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Prevention of experimental enc ...... ompatibility complex proteins.
@ast
Prevention of experimental enc ...... ompatibility complex proteins.
@en
Prevention of experimental enc ...... ompatibility complex proteins.
@nl
type
label
Prevention of experimental enc ...... ompatibility complex proteins.
@ast
Prevention of experimental enc ...... ompatibility complex proteins.
@en
Prevention of experimental enc ...... ompatibility complex proteins.
@nl
prefLabel
Prevention of experimental enc ...... ompatibility complex proteins.
@ast
Prevention of experimental enc ...... ompatibility complex proteins.
@en
Prevention of experimental enc ...... ompatibility complex proteins.
@nl
P2093
P2860
P356
P1476
Prevention of experimental enc ...... ompatibility complex proteins.
@en
P2093
Hodgkinson S
Mitchell DJ
Rothbard JB
Steinman L
P2860
P304
P356
10.1073/PNAS.86.23.9470
P407
P577
1989-12-01T00:00:00Z